Multiple Sclerosis

April / Previous Editions

Lifespan Neurodegeneration Of The Human Brain In Multiple Sclerosis

Using MRI data from more than 40,000 subjects, this study compares regional brain atrophy in people with MS as compared to normal controls and models its progression over time. The most pronounced atrophy related to MS started in deep grey matter structures (mainly thalamus, pallidum and putamen) then spread through the ventral diencephalon (a structure regrouping the hypothalamus, mammillary body, subthalamic nuclei, substantia nigra, red nucleus, lateral geniculate nucleus, and medial geniculate nucleus) to finally reach the brainstem.

The mean age of symptom onset in this cohort was 32, more than ten years after the first indication of atrophy in the thalamus.

Click Here to View the Full Slide Deck

Clinical Follow-Up

We asked the authors of last month's feature about the clinical implications of their biomarker panel.

How do you see this biomarker panel being integrated into patient management?
Do you have trials planned to consider clinical integration?
How does it compare to other biomarker panels currently under investigation?

Click Here to View the Author's Response

Other Recent Research of Note:

Preprints

CD4+ T cell mitochondrial genotype in Multiple Sclerosis: a cross-sectional and longitudinal analysis

DropCite Index:

An EBV-associated atypical B cell signature in clinically isolated syndrome is implicated in progression of multiple sclerosis

DropCite Index:

Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes

DropCite Index:

GEO Data Sets Analysis On Mechanism of Action of IFNÎ²-1a Treatment in Multiple Sclerosis

DropCite Index:

Publications

Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.

Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis.

Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.

Research Related to the Featured Preprint:

A. Eshaghi et al., “Deep grey matter volume loss drives disability worsening in multiple sclerosis.” bioRxiv, p. 182006, Aug. 29, 2017. doi: 10.1101/182006.

A. Eshaghi et al., “Progression of regional grey matter atrophy in multiple sclerosis.” bioRxiv, p. 190116, Sep. 19, 2017. doi: 10.1101/190116.

J. H. Cole et al., “Accelerated brain ageing and disability in multiple sclerosis.” bioRxiv, p. 584888, Mar. 23, 2019. doi: 10.1101/584888.

R. Meijboom et al., “Patterns of brain degeneration in early-stage relapsing-remitting multiple sclerosis.” medRxiv, p. 2021.11.18.21266506, Jan. 18, 2022. doi: 10.1101/2021.11.18.21266506.

S. Klistorner, M. H. Barnett, S. L. Graham, C. Yiannikas, J. Parratt, and A. Klistorner, “Mechanisms of central brain atrophy in multiple sclerosis.” medRxiv, p. 2022.03.28.22273015, Apr. 02, 2022. doi: 10.1101/2022.03.28.22273015.

M. Filippi et al., “Gray matter damage predicts the accumulation of disability 13 years later in MS,” Neurology, vol. 81, no. 20, pp. 1759–1767, Nov. 2013, doi: 10.1212/01.wnl.0000435551.90824.d0.